|
|
Article: Bavarian Nordic Initiate a Phase II Clinical Trial with IMVAMUNE(TM) in HIV Infected Patients.
- Article from:
- PR Newswire Europe
- Article date:
- July 20, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
COPENHAGEN, July 20 /PRNewswire/ -- Bavarian Nordic has initiated a Phase II trial to investigate the safety and immunogenicity of IMVAMUNE(TM) in HIV infected subjects. The trial involves 150 volunteers and is being conducted at 5 sites in the United States. This is Bavarian Nordic's second clinical study to evaluate the safety of IMVAMUNE(TM) in HIV infected patients and are the only studies evaluating MVA as a safe smallpox vaccine in this population of people, which are contradicted to traditional smallpox vaccines.
Recently, Bavarian Nordic also completed enrolment and vaccination in a Phase I clinical study with subjects suffering from atopic ...